Oral & Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Radiation Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Arch Oral Biol. 2017 Oct;82:160-165. doi: 10.1016/j.archoralbio.2017.06.011. Epub 2017 Jun 15.
Squamous cell carcinoma (SCC) is the sixth most frequent malignant tumor of the head and neck region. Despite advances in therapeutic options over the last decades, the rate of mortality and morbidity has not been improved markedly. A small subset of cells, cancer stem cells (CSCs), with self-renewal properties have become a major focus of current cancer research. CD44 and p63 are identified as candidate stem cell markers in normal squamous epithelium and SCC. The role of these markers in oral squamous cell carcinoma (OSCC) is still debatable. The aim of this study was to evaluate immunohistochemical expression of these markers in OSCC samples and also correlates the expression of these markers with some clinicopathological parameters of prognostic significance including histological grading, TNM staging, overall survival (OS) rate as well as patients' age, gender, and tumor location. CD44 and p63 were expressed in all studied lesions with different degrees. Statistically significant difference was observed between CD44 and p63 expression with tumor grade and stage with higher expression in high grade and advanced OSCCs. No significant relationship was detected between markers immunoreactivity and patients age, gender, tumor location as well as OS. These markers can possibly advance our understanding of the initiating mechanisms and pathogenesis of OSCC and also result in novel therapeutic target in cancer treatment.
鳞状细胞癌(SCC)是头颈部区域第六大常见恶性肿瘤。尽管在过去几十年中治疗选择有所进步,但死亡率和发病率并没有显著改善。一小部分具有自我更新特性的细胞,即癌症干细胞(CSC),已成为当前癌症研究的主要焦点。CD44 和 p63 被确定为正常鳞状上皮和 SCC 中的候选干细胞标志物。这些标志物在口腔鳞状细胞癌(OSCC)中的作用仍存在争议。本研究旨在评估这些标志物在 OSCC 样本中的免疫组织化学表达,并将这些标志物的表达与一些具有预后意义的临床病理参数相关联,包括组织学分级、TNM 分期、总生存率(OS)以及患者年龄、性别和肿瘤位置。CD44 和 p63 在所有研究病变中均有不同程度的表达。CD44 和 p63 的表达与肿瘤分级和分期之间存在统计学显著差异,在高级别和晚期 OSCC 中表达更高。未检测到标志物免疫反应性与患者年龄、性别、肿瘤位置和 OS 之间存在显著关系。这些标志物可能有助于我们更好地理解 OSCC 的起始机制和发病机制,并为癌症治疗提供新的治疗靶点。